Pharmaceutical intervention in the rational use of intravenous omeprazole

Abstract

Objective: To describe the pharmaceutical interventions of a vertical clinical pharmacy service to promote the rational use of intravenous omeprazole. Methods: A prospective and descriptive study carried out at a university hospital in the Midwestern Region of Brazil, from November 2014 to May 2015. The service consisted of the analysis of adequacy of the route of administration of omeprazole in relation to the clinical conditions of the patient, as well as the use of the appropriate diluent. Interventions were recorded in medical records and subsequently evaluated for acceptance. Results: A total of 770 prescriptions were evaluated. Interventions related to diluent replacement were more accepted (p<0.001), and surgeons were the specialty that used the intravenous route inappropriately (p<0.001). Conclusion: Although partially accepted, pharmaceutical interventions could contribute to improve patient safety, since they allowed the use of a safer route of administration.

Evolution of Intravenous Medication Errors and Preventive Systemic Defenses in Hospital Settings—A Narrative Review of Recent Evidence

“…lww.com/JPS/A612). The studies were conducted in the United States (n = 16), [47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] the United Kingdom (n = 7), [63][64][65][66][67][68][69] Australia (n = 3), [70][71][72] Brazil (n = 3), [73][74][75] Spain (n = 3), [76][77][78] Mexico (n = 2), 79,80 Saudi Arabia (n = 2), 81,82 Singapore (n = 2), 83,84 Canada (n = 1), 85 China (n = 1), 86 France (n = 1), 87 Germany (n = 1), 88 Italy (n = 1), 89 Netherlands (n = 1), 90 and Switzerland FIGURE 2. Outline of the narrative review process, analysis of the included articles (n = 63), and comparison to our previous systematic reviews.…”

“…91 Some studies (n = 2) were carried out in multiple countries. 92,93 The studies were conducted in hospital settings without a specification of a specialty area (n = 10), 55,56,[61][62][63]66,73,76,82,90 adult ICU (n = 9), 49,50,52,69,75,[78][79][80]92 hospital pharmacy (n = 7), 47,51,[57][58][59][60]93 pediatric intensive care unit (n = 5), 65,68,72,74,77 pediatric hospital (n = 3), 54,64,71 emergency department (n = 2), 70,84 anesthesia department (n = 1), 87 cancer hospital (n = 1), 86 and pediatric emergency department (n = 1). 81 Some studies (n = 8) were carried out in simulated environments comprising an anesthesia setting (n = 2), 83,88 hospital setting (n = 2), 48,67 ICU (n = 1), 85 NICU (n = 1), ...…”

“…retrospective analysis of smart infusion pump alert log data (n = 5), 55,62,77,80,82 studies measuring costs or cost effectiveness of the studied defense (n = 4), 66,74,87,90 observational intervention studies (n = 3), 61,71,73 retrospective or observational studies measuring drug consumption (n = 2), 52,79 chart reviews (n = 2), 70,72 and studies to design and develop systemic defenses (n = 2). 65,92 Other methods included an analysis of administration error reports (n = 1), 54 a survey study (n = 1), 84 healthcare failure mode and effects analysis (HFMEA) (n = 1), 86 a systematic review (n = 1), 78 and a systematic review with a meta-analysis (n = 1).…”

Perfil do uso do medicamento domperidona em pacientes idosos internados em um hospital universitário

“…O número de medicamentos combinados por paciente apresentou mediana de 3,0 (IQR 1,0), para 20 paciente a combinação entre os medicamentos de risco citado variou de Tabela 3 -Dados da prescrição dos pacientes internatos ≥60 anos em uso de domperidona comprimido de um hospital universitário Alagoas, Brasil, em 2020. A incidência do omeprazol na prescrição é esperado por ser um IBP, pertencente a uma classe de medicamento considerada a mais prescrita mundialmente (Araújo et al, 2020) pela sua eficácia em diminuir a produção da secreção gástrica contribuindo na cura e prevenção dos distúrbios gástricos (Delcher et al, 2015). Porém estudos em uma população geriátrica demonstrou prolongamento no intervalo de QT no uso concomitante do omeprazol e o citalopram proveniente de uma interação medicamentosa promovido pela inibição da enzima CYP2C19 e neste mesmo estudo o omeprazol foi classificado como inibidor fraco da CYP3A4 (Braz et al, 2018), enzima esta que atua como a principal via de metabolização do domperidona (ANVISA, 2022), dados estes que corroboram com a classificação de risco descrito no CredibleMeds como condicional.…”

Professional and Academic Perspectives of Pharmacy Students: A Cross Sectional-Study from Brazil

“…In Brazil, approximately 230,000 pharmacists are registered in the class council of the states to exert their professional skills in the pharmaceutical sciences (Araújo et al, 2020). Approximately 506 new professionals are registered each year in the pharmacy councils of the states of the Brazilian Amazon basin.…”